Romanian Society of Pharmaceutical Sciences

« Back to Farmacia Journal 3/2022

EFFECT OF ARIPIPRAZOLE COMBINED WITH OLANZAPINE ON THE CLINICAL EFFICACY OF SCHIZOPHRENIA

TIANCHENG JIA 1*, XUE LEN 2, ZHILIAN PI 1, ZHE HONG 1, JIN FENG 1, CHUNHE MA 1

1Department of Psychiatry, Jiande Fourth People's Hospital, Jiande, 311612, Zhejiang, China
2Department of Obstetrics and Gynecology, Jiande Maternal and Child Health Hospital, Jiande, 311600, Zhejiang, China

Download Full Article PDF

In this study, the clinical efficacy of aripiprazole combined with olanzapine in the treatment of schizophrenia was analysed. Sixty-eight schizophrenic patients were included in the study and randomly divided into a control group (34 cases) and an experimental group (34 cases) and underwent treatment for 8 weeks. The patients from the control group received olanzapine started with 10-20 mg/day and adjusted according to clinical evolution for 8 weeks. The patients from the experimental group received olanzapine in the same dose associated with aripiprazole starting with 10 mg/day and adjusted according to clinical evolution for 8 weeks. The results showed that the clinical total effective rate of the control group was significantly reduced compared with the experimental group. The addition of aripiprazole to the olanzapine significantly decreases the positive and negative syndrome scale (PANSS) score, total cholesterol, triglycerides, blood glucose levels, free thyroxine (FT4), triiodothyronine (T3), thyroxine (T4) levels, level of neuron-specific enolase (NSE) and the incidence of adverse reactions compared with the control group, and significantly increase the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) score, thyroid-stimulating hormone (TSH) level, brain-derived neurotrophic factor (BDNF) levels compared with the control group. In conclusion, aripiprazole combined with olanzapine has a significant clinical effect on schizophrenic patients, can improve glucose and fat metabolism and cognitive function, and decrease neurological dysfunction, with minor adverse reactions and good medication safety.